VRTX
VERTEX PHARMACEUTICALS INC / MACompany Information
- Company Name
- VERTEX PHARMACEUTICALS INC / MA
- CIK
- CIK0000875320
- Category
- Large accelerated filer
- Ticker: Exchange
- VRTX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- VRTX
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-08-06
- Last sale
- 2026-06-26
- Shares purchased (TTM)
- 15,000
- Shares sold (TTM)
- 310,657
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 219,695,970
- Shares outstanding
- 254,100,000
- Ownership
- 86.46%
Earnings Market Reaction
- Filing date
- 2026-08-04
- Price on filing date
- —
- 1-month reaction
- 13.16%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 6,144 | 5,493 | 5,085 | 4,940 | 4,972 | 4,675 | 4,570 | 5,239 | 4,580 | 9,158 | 10,369 | 11,110 | ||||||
| Marketable Securities Current | 1,709 | 1,754 | 1,523 | 1,347 | 1,411 | 1,527 | 1,546 | 1,285 | 1,215 | 1,013 | 849 | 818 | ||||||
| Accounts Receivable Net Current | 2,134 | 1,996 | 2,053 | 1,946 | 1,894 | 1,805 | 1,609 | 1,751 | 1,656 | 1,793 | 1,563 | 1,539 | ||||||
| Inventory Net | 1,765 | 1,767 | 1,687 | 1,627 | 1,499 | 1,360 | 1,205 | 1,080 | 915 | 813 | 739 | 689 | ||||||
| Prepaid Expense And Other Assets Current | 792 | 721 | 853 | 709 | 652 | 643 | 666 | 449 | 575 | 511 | 624 | 540 | ||||||
| Assets Current | 12,544 | 11,730 | 11,201 | 10,570 | 10,428 | 10,009 | 9,596 | 9,804 | 8,942 | 13,289 | 14,144 | 14,696 | ||||||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 1,665 | 1,608 | 1,520 | 1,425 | 1,335 | 1,296 | 1,228 | 1,118 | 1,201 | 1,173 | 1,159 | 1,124 | ||||||
| Goodwill | 1,088 | 1,088 | 1,088 | 1,088 | 1,088 | 1,088 | 1,088 | 1,088 | 1,088 | 1,088 | 1,088 | 1,088 | ||||||
| Intangible Assets Net Excluding Goodwill | 413 | 419 | 424 | 430 | 436 | 441 | 826 | 832 | 838 | 835 | 840 | 604 | ||||||
| Deferred Income Tax Assets Net | 3,011 | 2,948 | 2,898 | 2,937 | 2,712 | 2,544 | 2,331 | 2,309 | 2,186 | 1,963 | 1,812 | 1,729 | ||||||
| Operating Lease Right Of Use Asset | 1,663 | 1,685 | 1,563 | 1,592 | 1,314 | 1,339 | 1,357 | 1,396 | 570 | 313 | 294 | 311 | ||||||
| Marketable Securities Noncurrent | 5,789 | 5,750 | 5,712 | 5,723 | 5,646 | 5,157 | 5,108 | 4,704 | 4,393 | 4,381 | 2,498 | 1,700 | ||||||
| Other Assets Noncurrent | 1,251 | 1,256 | 1,237 | 1,098 | 1,079 | 1,007 | 999 | 990 | 916 | 876 | 895 | 475 | ||||||
| Assets | 27,423 | 26,484 | 25,643 | 24,862 | 24,037 | 22,881 | 22,533 | 22,240 | 20,132 | 23,917 | 22,730 | 21,726 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 430 | 489 | 462 | 420 | 442 | 445 | 413 | 396 | 328 | 351 | 365 | 376 | ||||||
| Accrued Liabilities Current | 3,179 | 2,984 | 2,971 | 3,614 | 3,271 | 2,952 | 2,789 | 3,220 | 2,940 | 2,796 | 2,655 | 2,907 | ||||||
| Other Liabilities Current | 329 | 407 | 428 | 442 | 425 | 386 | 363 | 358 | 279 | 649 | 527 | 316 | ||||||
| Liabilities Current | 3,938 | 3,881 | 3,861 | 4,475 | 4,138 | 3,783 | 3,565 | 3,973 | 3,547 | 3,796 | 3,547 | 3,599 | ||||||
| Operating Lease Liability Noncurrent | 1,978 | 1,987 | 1,847 | 1,835 | 1,527 | 1,538 | 1,544 | 1,589 | 587 | 360 | 349 | 354 | ||||||
| Finance Lease Liability Noncurrent | - | - | - | - | - | 111 | 113 | 114 | 347 | 362 | 376 | 390 | ||||||
| Other Liabilities Noncurrent | 1,260 | 1,255 | 1,270 | 1,233 | 1,196 | 952 | 1,015 | 933 | 877 | 854 | 878 | 869 | ||||||
| Liabilities | 7,175 | 7,123 | 6,977 | 7,544 | 6,861 | 6,384 | 6,124 | 6,609 | 5,357 | 5,371 | 5,150 | 5,213 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Commitments And Contingencies | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Additional Paid In Capital Common Stock | 4,506 | 4,743 | 5,119 | 5,012 | 5,988 | 6,173 | 6,672 | 6,906 | 7,101 | 7,285 | 7,450 | 7,340 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 49 | 25 | -16 | -65 | -101 | 68 | 128 | 29 | 23 | 17 | -14 | -3 | ||||||
| Retained Earnings Accumulated Deficit | 15,691 | 14,591 | 13,560 | 12,369 | 11,286 | 10,253 | 9,607 | 8,694 | 7,648 | 11,242 | 10,142 | 9,174 | ||||||
| Stockholders Equity | 20,248 | 19,362 | 18,666 | 17,319 | 17,175 | 16,496 | 16,410 | 15,631 | 14,775 | 18,547 | 17,580 | 16,513 | ||||||
| Liabilities And Stockholders Equity | 27,423 | 26,484 | 25,643 | 24,862 | 24,037 | 22,881 | 22,533 | 22,240 | 20,132 | 23,917 | 22,730 | 21,726 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 253 | 254 | 254 | 254 | 256 | 257 | 257 | 258 | 258 | 258 | 258 | 258 | ||||||
| Shares Outstanding | 253 | 254 | 254 | 254 | 256 | 257 | 257 | 258 | 258 | 258 | 258 | 258 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialVERTEX PHARMACEUTICALS INC / MA (VRTX) — SEC Financial Statements & Analysis
VERTEX PHARMACEUTICALS INC / MA (VRTX) is a pharmaceutical preparations company, incorporated in MA. VERTEX PHARMACEUTICALS INC / MA trades on Nasdaq as: VRTX. VERTEX PHARMACEUTICALS INC / MA (VRTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, VERTEX PHARMACEUTICALS INC / MA carries a market cap of $126.02B, a P/E ratio of 28.61x, a P/B ratio of 6.22x, a P/S ratio of 10.01x, an enterprise value of $119.87B, and an EV/EBITDA multiple of 23.98x. On profitability, it posts a gross margin of 86.00%, an operating margin of 37.95%, a net margin of 35.00%, a Return on Equity (ROE) of 23.54%, a Return on Assets (ROA) of 17.12%, and a Return on Invested Capital (ROIC) of 29.81%. Per share, it reports EPS of $17.36, diluted EPS of $17.26, free cash flow per share of $14.96, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 10.23% year-over-year, net income growth of 21.10% year-over-year, and EPS growth of 22.53% year-over-year. On the balance sheet, it maintains a current ratio of 3.19x, a quick ratio of 2.54x, working capital of $8.61B, a debt-to-equity ratio of 0.35x, a debt ratio of 0.26, an interest coverage ratio of 723.80x, free cash flow of $3.80B (TTM), and net debt of $-6.15B. Figures sourced from SEC EDGAR.
- Market Cap
- $126.02B
- P/E TTM
- 28.61x
- EPS TTM
- $17.36
- P/B TTM
- 6.22x
- ROE TTM
- 23.54%
- ROA TTM
- 17.12%
- Debt To Equity
- 0.35x
- Free Cash Flow TTM
- $3.80B
- Net Revenue TTM Growth 1Y
- 10.23%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is VERTEX PHARMACEUTICALS INC / MA in?
VERTEX PHARMACEUTICALS INC / MA (VRTX) operates in the Pharmaceutical Preparations industry.
What exchange does VRTX trade on?
VERTEX PHARMACEUTICALS INC / MA (VRTX) trades on the Nasdaq.
Where is VERTEX PHARMACEUTICALS INC / MA incorporated?
VERTEX PHARMACEUTICALS INC / MA is incorporated in MA.
When was VERTEX PHARMACEUTICALS INC / MA (VRTX)'s most recent SEC filing?
VERTEX PHARMACEUTICALS INC / MA (VRTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04.
What is VRTX's market cap?
VERTEX PHARMACEUTICALS INC / MA (VRTX) has a market capitalization of $126.02B as of 2026-06-30.
What is VRTX's P/E ratio?
VERTEX PHARMACEUTICALS INC / MA (VRTX)'s trailing twelve month P/E ratio is 28.61x as of 2026-06-30.
What is VRTX's EPS (earnings per share)?
VERTEX PHARMACEUTICALS INC / MA (VRTX)'s trailing twelve month EPS is $17.36 as of 2026-06-30.
What is VRTX's ROE (return on equity)?
VERTEX PHARMACEUTICALS INC / MA (VRTX)'s trailing twelve month Return on Equity (ROE) is 23.54% as of 2026-06-30.
What is VRTX's ROA (return on assets)?
VERTEX PHARMACEUTICALS INC / MA (VRTX)'s trailing twelve month Return on Assets (ROA) is 17.12% as of 2026-06-30.
What is VRTX's ROIC (return on invested capital)?
VERTEX PHARMACEUTICALS INC / MA (VRTX)'s trailing twelve month Return on Invested Capital (ROIC) is 29.81% as of 2026-06-30.
What is VRTX's EV/EBITDA?
VERTEX PHARMACEUTICALS INC / MA (VRTX)'s trailing twelve month EV/EBITDA is 23.98x as of 2026-06-30.